Lv3
370 积分 2022-02-14 加入
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
18小时前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
9天前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
9天前
已完结
The Drug-Dosing Conundrum in Oncology — When Less Is More
6个月前
已完结
A comparative study of adaptive trial designs for dose optimization
6个月前
已完结
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
6个月前
已完结
[Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence]
6个月前
已关闭
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics
6个月前
已完结
Cytokine Release Syndrome Biology and Management
6个月前
已完结
皖公网安备34019202002308
